DOI: 10.1128/JCM.44.3.923-927.2006
Article Figures & Data
Figures
- FIG. 1.
Typical Gram stain appearance of a sputum smear that grew S. pseudopneumoniae as the sole pathogen.
Tables
- TABLE 1.
Phenotypic and genotypic test results for strains of S. pseudopneumoniae
Isolatea Optochin zone size (mm)b Bile solublee AccuProbe resultf Plyc NOW antigen test resultf Rapid ID32 Strep result CO2 O2 Profile Identification 22 14 32 − + + + 64032441100 86.7% S. oralis II 28 10 32 − + + + 40012441100 65.5% S. mitis I 33.4% S. oralis II 35 14 24 − + + + 04012541100 73.8% S. mitis I 23.2% S. oralis II 78 14 28 − + + + 24002500000 36.7% Gemella haemolysans 83 12 34 − + + + 44012241100 95.9% S. oralis II 114 10 24 − + − + 44012541100 54.8% S. oralis II 42.5% S. mitis I 134 6 30 − + + + 44132544100 Unacceptable profile 147 6 26 − + − + 04112541100 98.2% S. mitis I 153 12 34 − + − + 44112641100 87.3% S. oralis II 169 13 32 − + + + 44112441100 93.4% S. mitis I 170 13 22 − + + + 64002400000 46.2% S. mitis II 178 8 26 − + + + 44112641100 87.3% S. oralis II 226 10 26 − + + + 04012541100 73.8% S. mitis I 23.2% S. oralis II 288 8 22 − + − + 64036641100 98.3% S. intermedius 369 6 26 − + + + 44012541100 54.8% S. oralis II 42.5% S. mitis I 407 6 26 − + + + 04002500000 48.5% G. haemolysans 418 8 22 − + + + 44112441100 93.4% S. mitis I 431 12 46 − + + + 44012441100 56.1% S. oralis II 43.5% S. mitis I 434 8 22 − + + + 24332441100 96.9% S. sanguis II 441 13 36 − + + + 64112544100 Unacceptable profile 445 6 36 − + + + 64012441100 91.9% S. oralis II 457 10 26 − + + + 64132541100 Unacceptable profile 458 6 24 − + + + 64012560100 Unacceptable profile 474 12 26 − + + + 44012441100 56.1% S. oralis II 43.5% S. mitis I 479 10 28 − + − + 64112441100 56.3% S. mitis I 43.4% S. oralis II 480 6 36 − + + + 04002401100 88.6% G. morbillorum 490 6 36 − + + + 44012441100 56.1% S. oralis II 43.5% S. mitis I 499 10 36 − + + + 44012441100 56.1% S. oralis II 43.5% S. mitis I 554 8 24 − + + + 44112441100 93.4% S. mitis I 589 10 26 − + + + 44002400000 Unacceptable profile 669 9 26 − + + + 44112441100 93.4% S. mitis I 705 10 30 − + + + 44012401100 77.0% S. oralis II 747 6 21 − + + + 44312441100 93.4% S. mitis I 773 8 26 − + + + 44012441100 56.1% S. oralis II 43.5% S. mitis I 785 6 24 − + + + 24012441100 71.4% S. oralis II 20.4% S. mitis I Reference straind 13 22 − + + + 44012441100 56.1% S. oralis II 43.5% S. mitis I ↵ a Isolate 28, 83, and 490 are from different sputum samples from the same patient.
↵ b Optochin susceptibility in 5% CO2 and in ambient (O2) environments.
↵ c Ply, pneumolysin gene. +, pneumolysin gene was detected; −, pneumolysin gene was not detected.
↵ d S. pseudopneumoniae NZRM4311 (ATCC BAA-960).
↵ e −, isolate was not bile soluble.
↵ f +, positive test result.
- TABLE 2.
Characteristics of patients with S. pseudopneumoniae isolated from sputum
Patient Age (yr) Sex Clinical presentation Current or ex-smokerc Chest X-ray infiltratea Other bacteria in sputum Antibiotic treatmentb Outcome 1 64 F Exacerbation of COPD + − H. influenzae Amx/Cla Improved 2 82 M Motor neuron disease, COPD + + None Improved 3 63 M Cough, ischemic heart disease, diabetes − + Amx/Cla Readmitted with pneumonia 4 63 M Amaurosis fugax, cough, COPD + − None Improved 5 89 F Lobar pneumonia, COPD + + Amoxicillin Improved 6 80 M Ischemic heart disease, cough, COPD + + None Readmitted with pneumonia 7 51 F Exacerbation of COPD + − Ciprofloxacin Improved 8 15 M Bronchiectasis − − H. influenzae Cefuroxime Improved 9 78 F Pubic ramus fractures, cough, COPD + − H. influenzae Amx/Cla Improved 10 57 M Exacerbation of COPD + + Amx/Cla Improved 11 78 M Fractures, cough, COPD + + Amx/Cla Improved 12 86 M Exacerbation of COPD + − H. influenzae Amoxicillin Improved 13 78 M Exacerbation of COPD + + Clarithromycin Improved 14 77 M Exacerbation of COPD + − Erythromycin Improved 15 62 M Exacerbation of COPD + ND H. influenzae Amx/Cla Improved 16 55 F Ischemic heart disease, cough + − None Improved 17 81 F Exacerbation of COPD + − Amoxicillin Improved 18 68 M Exacerbation of COPD + − H. influenzae Amoxicillin Improved 19 52 F Bronchiectasis − − H. influenzae Amoxicillin Improved 20 77 M Exacerbation of COPD + + H. influenzae Roxythromycin Improved 21 28 F Asthma + ND Unknown Unknown 22 74 M Lung cancer, COPD + − H. influenzae None Improved M. catarrhalis 23 69 F Exacerbation of COPD + − Amx/Cla Improved 24 53 M Bronchiectasis + ND None Improved 25 50 F Exacerbation of COPD + + Amx/Cla Improved 26 61 F Exacerbation of COPD + − H. influenzae Amx/Cla Improved Pseudomonas aeruginosa 27 77 M Renal cell carcinoma, COPD + − Roxythromycin Improved 28 53 M Asthma, COPD + − Unknown Unknown 29 66 F Exacerbation of COPD + − None Improved 30 72 M Exacerbation of COPD + − Ciprofloxacin Improved 31 74 F Exacerbation of COPD + − None Improved 32 75 M Prostate cancer, cough + + Amx/Cla Improved 33 63 F Exacerbation of COPD + − Amx/Cla Improved - TABLE 3.
Clinical features of patients who had S. pseudopneumoniae cultured from sputum compared with control patients who had S. pneumoniae cultured from sputum
Clinical feature No. of patients with characteristic/no. with available information (%) Odds ratio (95% CI)a P value Cases Controls History of COPD 26/33 (79) 36/66 (55) 5.00 (1.67 to 20.11) 0.002 Exacerbation of COPD 17/33 (52) 12/66 (18) 6.50 (2.61 to 16.20) 0.0001 History of bronchiectasis 3/33 (9) 4/66 (6) 1.50 (0.36 to 7.23) 0.75 History of asthma 2/33 (6) 4/66 (6) 1.00 (0.07 to 13.80) 1.00 Current or ex-smoker 30/33 (91) 50/64 (78) 3.00 (0.91 to 12.76) 0.08 Chest radiographic infiltrates 10/30 (33) 29/54 (54) 0.45 (0.18 to 1.03) 0.06 ↵ a CI, confidence interval.
